Medical Innovation: Equillium's Itolizumab Delivers Promising Results in Phase 2 Trial

Equillium Inc.'s itolizumab has demonstrated significant potential in treating moderate to severe ulcerative colitis. In a recent Phase 2 study, the drug achieved a 16.7% endoscopic remission rate, matching the performance of adalimumab, a widely used biologic treatment. The study also revealed a 23.3% clinical remission rate for itolizumab at 12 weeks, surpassing both adalimumab (20.0%) and placebo (10.0%). These promising results highlight itolizumab's efficacy in managing this challenging inflammatory bowel condition, potentially offering new hope for patients seeking alternative treatment options.

Source: Business Wire